Osteopathic Medical Degree
- Doctor of Osteopathic Medicine – Oklahoma State University College of Osteopathic Medicine, Tulsa, OK
Internship / Residency
- Clinical Genetics Residency – National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
- Pediatrics Residency – University of Oklahoma-Tulsa, Tulsa, OK
- Medical Internship – Oklahoma State University College of Osteopathic Medicine, Tulsa, OK
- Bachelor of Arts in Biology – Northeastern State University, Tahlequah, OK
- Fellow, American College of Medical Genetics
“I look at Cancer Treatment Centers of America® (CTCA) as being cutting edge. Health care today is about the masses and CTCA® envisions the 'one.' Tumors are very unique and patients should be treated that way,” says Dr. Michael Kayser, Medical Director of Genetic Services and clinical geneticist at CTCA at Southwestern Regional Medical Center. A Fellow of the American College of Medical Genetics, Dr. Kayser is board certified in clinical genetics and clinical biochemical genetics.
Dr. Kayser earned a Doctor of Osteopathic Medicine degree from Oklahoma State University (OSU) College of Osteopathic Medicine in Tulsa, where he subsequently completed a medical internship at OSU Medical Center.
He then completed a three-year residency in pediatrics at the University of Oklahoma-Tulsa. Following that program he completed a clinical genetics residency, and a fellowship in clinical biochemical genetics, at the National Human Genome Research Institute, National Institutes of Health, in Bethesda, MD, during which time he spent two years as Assistant Clinical Investigator.
Dr. Kayser holds a bachelor’s degree in Biology from Northeastern State University in Tahlequah, OK.
Prior to joining CTCA, Dr. Kayser served as Medical Director of the Warren Clinic Center for Genetics and Center for Genetic Testing at Saint Francis in Tulsa. He also served as Director of the Clinical Mass Spectrometry and Biochemical Genetics Laboratories.
Dr. Kayser was an Adjunct Clinical Assistant Professor at OSU College of Osteopathic Medicine Center for Health Sciences and a Clinical Assistant Professor at the University of Oklahoma College of Medicine. He has been an Investigator at the National Cancer Institute (NCI) since 2010.
Of his decision to join CTCA in September 2013, Dr. Kayser says: “A lot in health care is broken, and I wanted to be a part of the CTCA model because of what they look to do for their patients.”
As a board certified clinical geneticist, Dr. Kayser partners with patients’ oncologists and care teams at CTCA to find personalized/targeted therapies for each individual. He says: “Cancer genetics is tremendously exciting and fast moving. In my opinion, cancer is not going to be classified by the location of cancer, but the molecular causes of an individual tumor.”
Dr. Kayser adds that many new cancer treatments are already based on genetic testing of tumors: “Cancer treatment is going to continue to evolve over the next five to 10 years. We’ll be able to find out what’s wrong with the cell on a molecular level and target therapies to these abnormalities. It’s testing that actionable—we can treat based on our findings.”
For patients with early onset or strong family histories of cancer, Dr. Kayser says genetic testing provides an opportunity to find out if there is risk for other cancers or if there are family members who need to be tested. With this information we can tailor preventive or surveillance strategies to the individual.
Dr. Kayser has contributed to numerous medical publications, abstracts and research projects. He is a member of the Oklahoma Genetics Advisory Council and the Oklahoma Genetic Counseling Advisory Committee, as well as the American Society of Human Genetics, the American Medical Association, and the American Osteopathic Association, and the Society of Inherited Metabolic Disorders.
He is married with a daughter and a son.
Patient Ratings and Comments
Star ratings and comments are only available for medical oncologists and radiation oncologists. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.